AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 80 filers reported holding AVADEL PHARMACEUTICALS PLC in Q1 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $109,601,329 | -11.6% | 10,638,307 | +41.4% | 0.07% | -6.5% |
| Q2 2023 | $124,010,891 | +98.4% | 7,522,545 | +10.2% | 0.08% | +87.8% |
| Q1 2023 | $62,493,574 | +624.3% | 6,826,787 | +465.4% | 0.04% | +583.3% |
| Q4 2022 | $8,627,802 | -10.4% | 1,207,530 | -14.4% | 0.01% | +20.0% |
| Q1 2022 | $9,626,000 | +18.6% | 1,410,387 | +40.6% | 0.01% | +66.7% |
| Q4 2021 | $8,117,000 | +2.3% | 1,003,318 | +23.7% | 0.00% | 0.0% |
| Q3 2021 | $7,938,000 | +58.9% | 811,257 | +9.2% | 0.00% | +50.0% |
| Q2 2021 | $4,995,000 | +117.6% | 742,772 | +193.3% | 0.00% | +100.0% |
| Q1 2021 | $2,296,000 | +49.3% | 253,227 | +10.4% | 0.00% | 0.0% |
| Q4 2020 | $1,538,000 | -93.2% | 229,402 | -89.4% | 0.00% | -92.9% |
| Q3 2017 | $22,618,000 | -6.1% | 2,154,082 | -1.4% | 0.01% | -12.5% |
| Q2 2017 | $24,100,000 | – | 2,184,911 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 985,210 | $10,345,000 | 6.10% |
| Broadfin Capital, LLC | 3,568,122 | $37,465,000 | 5.54% |
| JW Asset Management, LLC | 444,439 | $4,667,000 | 3.42% |
| ARMISTICE CAPITAL, LLC | 1,688,000 | $17,724,000 | 2.09% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,655,494 | $38,383,000 | 1.73% |
| FALCON POINT CAPITAL, LLC | 661,490 | $6,284,000 | 0.91% |
| KNOTT DAVID M | 158,555 | $1,665,000 | 0.71% |
| Perceptive Advisors | 3,098,010 | $32,530,000 | 0.62% |
| Sio Capital Management, LLC | 91,413 | $960,000 | 0.50% |
| HEARTLAND ADVISORS INC | 700,000 | $7,350,000 | 0.48% |